Mylan launches generic transdermal contraceptive


Aiming to capture a chunk of Janssen Pharmaceuticals' (JNJ) ORTHO EVRA (Norelgestromin/Ethinyl Estradiol Transdermal System 150/35 mcg/day) $150M U.S. sales, Mylan (MYL) launches its generic equivalent XULANE.

The product is indicated for the prevention of pregnancy in women who use a transdermal patch as a method of contraception.

According to IMS Health, Mylan has 300 ANDAs pending FDA approval representing $104.5B in branded sales. 42 are first-to-file submissions representing over $25B in branded sales.

From other sites
Comments (1)
  • maybenot
    , contributor
    Comments (6760) | Send Message
     
    Good. Anything to help women's health is a good thing.

     

    Long JNJ
    17 Apr 2014, 09:36 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs